Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ImmunityBio FDA Warning, Stock Drop
Regulatory securities lawsuit

ImmunityBio FDA Warning, Stock Drop

Analysis based on 10 articles · First reported May 01, 2026 · Last updated May 09, 2026

Sentiment
-50
Attention
4
Articles
10
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is impacted by the significant 21% stock price drop of ImmunityBio, Inc. due to the United States — Food and Drug Administration's warning letter, leading to a securities class action lawsuit. This event highlights regulatory risks in the biotechnology sector and the potential for substantial financial losses for investors.

Biotechnology Legal Services
Event Summary

ImmunityBio, Inc. is facing a securities class action lawsuit initiated by Kahn Swick & Foti, LLC, following a 21% decline in its stock price. The decline occurred after the United States — Food and Drug Administration issued a warning letter to ImmunityBio, Inc. CEO Richard Adcock on March 13, 2026. The letter stated that a television advertisement and podcast for ImmunityBio, Inc.'s cancer therapy, Anktiva, misrepresented the product, creating a misleading impression that it could cure and prevent all cancer, thereby violating the Federal Food, Drug, and Cosmetic Act. Investors who purchased ImmunityBio, Inc. securities between January 19, 2026, and March 24, 2026, have until May 26, 2026, to file lead plaintiff applications in the lawsuit.

Key Actions
95 Kahn Swick & Foti filed class action lawsuit ImmunityBio
90 United States — Food and Drug Administration issued warning letter ImmunityBio
85 ImmunityBio overstated capabilities
Entities Involved
stock
ImmunityBio
ImmunityBio is facing a securities class action lawsuit due to a significant drop in its stock price following a US Food and Drug Administration warning letter regarding misleading advertisements for its cancer therapy, Anktiva.
Importance 100 Sentiment -70
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a warning letter to ImmunityBio, Inc. regarding misleading promotional communications for Anktiva, which led to the company's stock decline and subsequent lawsuit.
Importance 80 Sentiment 0
priv
Kahn Swick & Foti
Kahn Swick & Foti is a law firm representing investors in the securities class action lawsuit against ImmunityBio, Inc.
Importance 60 Sentiment 20
per
Richard Adcock
Richard Adcock, CEO of ImmunityBio, Inc., received the warning letter from the United States — Food and Drug Administration concerning the misleading advertisements.
Importance 40 Sentiment -50
per
Lewis Kahn
Lewis Kahn is the Managing Partner of Kahn Swick & Foti, LLC, and is involved in reminding investors about the class action lawsuit.
Importance 20 Sentiment 10
per
Charles Foti
Charles Foti is a partner at Kahn Swick & Foti, LLC, and a former Attorney General of Louisiana, involved in the securities class action lawsuit.
Importance 20 Sentiment 10
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.